This study is currently not recruiting participants.

Using Functional Image and Circulating Molecular Markers to Predict Tumor Control and Thoracic Toxicity in Treatment of Lung Cancer

Investigation of Imaging Techniques to Predict Cancer Treatment Outcomes

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to see if these scans help predict how well the treatment works for your cancer, how well your lungs, esophagus and heart function during treatment, and if treatment causes inflammation (irritation, swelling, redness due to injury).

Detailed description of study

The purpose of this study is to determine if tumor metabolic activity plus volume measured by 18F-FDG PET/CT and tissue/tumor perfusion measured by 62Cu-ETS-PET before and during treatment predicts CT tumor response 3 months after completion of treatment and 1 and 2 year local-regional progression-free survival; to determine if functional imaging based lung dose-volume histograms (DVH) more accurately predict changes in diffusion capacity of lung for carbon monoxide (DLCO) compared to the DVH based on simulationg CT; and to determine if baseline level, or changes in blood markers such as TGFbeta1 measured during the course of radiation, predict changes in DLCO.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lung cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates how imaging scans can predict the effectiveness of cancer treatment. It looks at how well your lungs, esophagus, and heart work during treatment and whether the treatment causes inflammation, which is swelling or redness due to injury.

The study uses special imaging techniques like 18F-FDG PET/CT and 62Cu-ETS-PET to measure tumor activity and blood flow before and during treatment. It aims to see if these measurements can predict how the tumor responds to treatment and the patient's survival without disease progression. The study also examines if these imaging techniques can better predict lung function changes compared to standard methods and if blood markers can predict lung function changes during radiation therapy.

  • Who can participate: Participants must be adults aged 18 years or older with a confirmed diagnosis of cancer. Key eligibility factors include not having undergone prior radiation therapy and having adequate organ function.
  • Study details: Participants will undergo imaging scans using 18F-FDG PET/CT and 62Cu-ETS-PET at specified intervals. The study will compare these results with standard imaging methods to assess their predictive value. A placebo is not involved in this study.
Updated on 19 Feb 2024. Study ID: 1611045952 (IUSCC-0596)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team